Sugi Predict

Sugi Predict / Compounds / SCHEMBL2925874

SCHEMBL2925874

SCHEMBL2925874

Nc1ccc2c(cnn2CCO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.50
▸ AURKA O14965 1/20 0.50
▸ DAPK3 O43293 1/20 0.50
▸ CSNK1A1 P48729 1/20 0.50
▸ GSK3A P49840 1/20 0.50
▸ LIMK1 P53667 1/20 0.50
▸ IKBKE Q14164 1/20 0.50
▸ MAPK14 Q16539 1/20 0.50
▸ TAOK1 Q7L7X3 1/20 0.50
▸ CLK4 Q9HAZ1 1/20 0.50
▸ DYRK1B Q9Y463 1/20 0.50
▸ KMO O15229 5/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ HTR2A P28223 3/20 0.43
▸ HTR2C P28335 3/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ GLS O94925 1/20 0.41
▸ PRKCI P41743 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320695 0.90 CHEK1 (0.48) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL30833639 0.87 HTR2A (0.54) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL14320854 0.87 HTR2A (0.54) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL29377819 0.83 CHEK1 (0.46) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL29200969 0.83 CHEK1 (0.50) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL14908603 0.83 CHEK1 (0.46) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL31304362 0.81 CHEK1 (0.44) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL4479034 0.80 KMO (0.46) KMOHTR2AHTR2CHTR2BGLS
SCHEMBL15447295 0.80 KMO (0.52) KMOHTR2AHTR2CHTR2BGLS
SCHEMBL29804486 0.80 KMO (0.52) KMOHTR2AHTR2CHTR2BGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101948433-B Method for separating and purifying substituted indazole isomer UNIV ZHENGZHOU 2012-05-09 — — CN claimed
CN-101948433-A Method for separating and purifying substituted indazole isomers UNIV ZHENGZHOU 2011-01-19 — — CN claimed
US-20240043439-A1 COMPOUNDS AS C5AR INHIBITORS KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) 2024-02-08 — — US disclosed
CN-116322683-A Compounds as C5AR inhibitors 科越医药(苏州)有限公司 2023-06-23 — — CN disclosed
EP-4192816-A1 COMPOUNDS AS C5AR INHIBITORS Kira Pharmaceuticals (Suzhou) Ltd. (CN) 2023-06-14 — — EP disclosed
WO-2022028586-A1 COMPOUNDS AS C5AR INHIBITORS KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) 2022-02-10 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9777020-B2 Furo-3-carboxamide derivatives and methods of use ABBVIE INC. (US) 2017-10-03 — — US disclosed
CN-101379060-B Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use TRANSTECH PHARMA INC 2012-05-23 — — CN disclosed
CN-101948433-B Method for separating and purifying substituted indazole isomer UNIV ZHENGZHOU 2012-05-09 — — CN disclosed
CN-101948433-A Method for separating and purifying substituted indazole isomers UNIV ZHENGZHOU 2011-01-19 — — CN disclosed
US-7820821-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2010-10-26 — — US disclosed
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors TRANSTECH PHARMA, INC. (US) 2010-06-17 — — US disclosed
CN-101379060-A Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use TRANSTECH PHARMA INC (US) 2009-03-04 — — CN disclosed
EP-1987028-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS Transtech Pharma, Inc. (US) 2008-11-05 — — EP disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 — — US disclosed
WO-2007095124-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK CHEK1 346/4885AURKA 716/4885DAPK3 496/4885
US-20240043439-A1 COMPOUNDS AS C5AR INHIBITORS C5AR1, C5AR2, C3AR1 CHEK1 1534/4885AURKA 1185/4885DAPK3 2573/4885
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors AURKC, AURKA, AURKB CHEK1 11/4885AURKA 2/4885DAPK3 362/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CHEK1 324/4885AURKA 640/4885DAPK3 467/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB CHEK1 11/4885AURKA 2/4885DAPK3 362/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CHEK1 324/4885AURKA 640/4885DAPK3 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.